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Objective: Omission of foot joints from composite global disease activity indices may lead to 
underestimation of foot and overall disease in rheumatoid arthritis (RA) and under-treatment. The 
aim of this study was to evaluate the measurement properties of the Rheumatoid Arthritis Foot 
Disease Activity Index-5 (RADAI-F5), a newly developed patient-reported outcome measure for 
capturing foot disease activity in people with RA.
Methods: Participants with RA self-completed the RADAI-F5, modified Rheumatoid Arthritis 
Disease Activity Index (mRADAI-5), Foot Function Index (FFI) and Foot Impact Scale 
impairment/footwear and activity/participation subscales (FIS-IF and FIS-AP). The 28 joint 
Disease Activity Score (DAS28-ESR) was also recorded. Subgroups completed the RADAI-F5 at 
1 week and 6-months. Psychometric properties including construct, content, and longitudinal 
validity, internal consistency, 1-week reproducibility, and responsiveness over 6-months were 
evaluated.
Results: Of 142 respondents, 103 were female, with a mean (standard deviation [SD]) age of 55 
years (12.5) and median (interquartile range [IQR]) RA disease duration of 10 (3.6-20.8) months. 
Theoretically consistent associations confirming construct validity were observed with mRADAI-
5 (0.789, 95% confidence interval [CI] 0.73-0.85), FFI (0.713, CI 0.62-0.79) and FIS-IF (0.695, CI 
0.66-0.82) (p<0.001); FFI-AP (0.478, p<0.001, CI 0.37-0.63) and the DAS28-ESR (0.379, 
p<0.001, CI 0.26-0.57). The RADAI-F5 demonstrated high internal consistency (Cronbach’s 
Alpha=0.90) and good reproducibility (ICC=0.868, p<0.001, CI 0.80-0.91; smallest detectable 
change=2.69). Content validity was confirmed with 82% rating the instrument relevant and easy to 
understand. 
Conclusion: The Rheumatoid Arthritis Foot Disease Activity Index-5 is a valid, reliable, 
responsive, clinically feasible PROM for measuring foot disease activity in RA.
Significance and Innovations
 The RADAI-F5 is the first patient-reported outcome measure designed to measure 
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 The RADAI-F5 is valid, reliable, responsive to change, and is feasible for use in clinical 
practice to measure foot disease in people with rheumatoid arthritis.
 The RADAI-F5 provides a means for measuring foot disease activity which is not captured 
by composite global disease activity indices such as the DAS28-ESR.  
Foot pain and disability are common in people who have rheumatoid arthritis (RA) with up to 90% 
experiencing disease-related foot symptoms during the course of their disease [1-4]. Synovitis in 
the small joints of the feet is present at the onset of RA in up to 70% of patients [5]. With the 
implementation of pharmacological management, prevalence of forefoot disease stabilises at 40-
50% after 2 years, but the prevalence of radiographic joint damage increases from 20% to 50% 
[5]. Approximately half of patients experience hindfoot joint problems [6], and clinically 
important soft tissue disease such as tibialis posterior tenosynovitis has a reported prevalence 
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The management of RA involves a ‘treat to target’ strategy that comprises regular review, 
objective assessment of disease activity and escalation of treatment if there is persistent disease 
activity. The aim is to achieve clinical remission (or low disease activity) [7,8]. Evaluation of 
inflammatory disease activity in RA involves the composite disease activity indices, of which the 
most widely used are the 28 joint count disease activity score (DAS28-ESR) [9], the clinical 
disease activity index (CDAI), and the simplified disease activity index (SDAI) [10]. These 
include 28-joint counts for tenderness and swelling that omit the joints and soft tissues of the feet 
[11]. Recent studies have demonstrated that approximately one-third of patients with RA classed 
as in DAS-28, SDAI and/or CDAI remission had clinically determined active foot synovitis 
[2,11,12]. Although the examination of foot joints is recommended [13], patients treated solely 
according to disease activity indices may be at risk of ongoing foot joint damage [11,14].
Various self-reported measures of RA disease activity have been validated including two versions 
of the Rheumatoid Arthritis Disease Activity Index (RADAI and modified RADAI-5) [15,16]. 
While these tools are more likely to capture foot disease activity than composite indices that 
exclude foot joints examination, they are not widely used in clinical practice. Several 
questionnaires have been developed for measuring RA-related foot problems including the Foot 
Impact Scale (FIS), Foot Function Index (FFI), and the Salford Rheumatoid Arthritis Foot 
Evaluation instrument (SAFE) [17-19]. These largely focus on disability as opposed to disease 
activity, and so have limited value for informing medical management. In addition, these tools 
lack feasibility in clinical practice due to high number of items and associated time burden, as well 
as absence of clinically meaningful categories for ease of interpretation. 
The current gold standard technique for measuring foot disease activity is magnetic resonance 
imaging (MRI) [20]. The more widely used imaging alternative is musculoskeletal ultrasound 
(MSUS), which is less sensitive than MRI and more specific than clinical examination of disease 
activity in RA [20-22].  However, these methods are not routinely used due to impracticalities 
such as cost of scans/equipment, time to perform scans, training needs and the risk of exposure to 
contrast agents. There is also a lack of consensus concerning how to approach medical 
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In summary, there is no widely used, validated and clinically feasible method for the assessment 
of foot disease activity in RA. We propose that a PROM designed to measure local foot disease 
activity may provide an opportunity for a treat-to-target medical approach which does not exclude 
foot disease activity. Accordingly, the purpose of this study was to develop and validate a new 
concise measure of foot disease activity for people with RA. 
  
PATIENTS AND METHODS
Development of the questionnaire
The design and content of the RADAI-F5 was derived from the modified Rheumatoid Arthritis 
Disease Activity Index-5 (mRADAI-5), a 5-item patient reported outcome measure for the self-
report of global disease activity, developed and evaluated by Leeb et al [16] and Rintelen et al 
[24]. It is completed in a numerical rating scale (NRS) format from 0 to 10, and scored by an 
average summary score ranging from 0-10. The RADAI-F5 was developed by editing the 
mRADAI-5 with an opening statement: “THINKING ONLY OF YOUR FEET”, and editing the 
original questions to subsequently read as follows: “How active was your arthritis IN YOUR 
FEET over the last 6 months?” (0 = completely inactive to 10 = extremely active); “How active is 
your FOOT arthritis today with respect to joint tenderness and swelling?” (0 = completely inactive 
to 10 extremely active); “How severe is your arthritis pain IN YOUR FEET today?” (0 = no pain 
to 10 = unbearable pain); “How would you describe your general FOOT health today?” (0 = very 
good to 10 = very bad); “Did you experience foot joint stiffness on awakening yesterday morning? 
If yes, how long was this stiffness IN YOUR FEET?” (0 = no stiffness to 10 stiffness the whole 
day). The RADAI-F5 is scored by an average summary score ranging from 0-10.
Study setting and participants
The two data sources for this study were 1) a primary RADAI-F5 validation study, conducted at 
rheumatology outpatient clinics at Glasgow Royal Infirmary, Gartnavel General Hospital and 
Stobhill Hospital within the Greater Glasgow and Clyde National Health Service Board, and 2) a 
larger randomised controlled trial, the details of which have been published previously [25]. 
Briefly, the trial was a multi-centre, parallel-group, randomised control trial with a 6- and 12-
months follow-up periods, with participants randomly allocated to either customised or 
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within NHS Grampian, Fife, Lanarkshire, Lothian Health Boards, Dorset Healthcare University 
Trust, and Homerton University Hospital Trust. 
Participants were included if they were aged between 18 and 75 years of age, with a definitive 
clinical diagnosis of RA. Patients were excluded if they were unable to read, write and/or 
understand the English language, or if they were diagnosed with other major medical conditions 
which could have diminished ability to distinguish between RA-related foot problems and those 
due to alternative disease mechanisms. Ethical approval was obtained from the West of Scotland 
Research Ethics Committee 5 (13/WS/0106) and the East of England Essex Research Ethics 
Committee (15/EE/0410). Participants were recruited consecutively and written consent was 
obtained from all participants. 
Data collection and measures
Demographic and clinical information was collected as baseline including age, sex and disease 
duration. The newly developed RADAI-F5 was collected at baseline, 1-week from baseline, and 6-
months from baseline. All other measurements were recorded at baseline and 6-months. The 
DAS28-ESR scores were recorded by rheumatologists as part of routine care and made available 
to researchers. The mRADAI-5 was collected as an additional self-reported measure of global 
disease activity [16]. Foot related impairments and disability were evaluated using the Foot 
Function Index (FFI) [18], and the Foot Impact Scale [17]. The FFI is a widely used and 
extensively validated 23-item PROM, completed using a 100mm VAS format, providing a mean 
summary score from 0-100 (higher scores indicating worse disability) [18]. The FIS is an 
extensively validated RA-specific 51-item measure with domains for impairment/footwear (21-
items) and activity limitation/participation restriction (30-items). It is completed using a yes/no 
dichotomous format and scores for domains calculated by summating “yes” responses (higher 
scores indicating worse disability) [17]. 
In order to evaluate the content validity and practical burden of the RADAI-F5 an additional 3 
items were evaluated; a 5 point Likert scale regarding questionnaire relevance to participants 
(ranging from extremely irrelevant to extremely relevant), a 5 point Likert scale regarding 
participants' opinion on the readability/understanding of the new questionnaire (ranging from very 
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Analysis
Data were analysed using SPSS 25 (IBM) and Excel 2016 (Microsoft). Descriptive statistics for 
age (median, inter-quartile range) in years, sex (female to male ratio) and disease duration 
(median, inter-quartile range) in months were generated for all participants at baseline. 
The RADAI-F5 was examined using factor analysis by principal component analysis to reveal the 
structure and item loading. Kaiser-Meyer-Olkin test and Bartlett’s test of sphericity were 
undertaken to determine data suitability for factor analysis.  The number of factors extracted was 
decided by a combination of Kaiser’s rule (eigenvalues greater than 1), examination of the scree 
plot, and interpretation of items’ contribution to the factor. 
To test internal consistency, we evaluated the inter-item correlation matrix and calculated 
Cronbach’s alpha, a measure of consistency between items in a scale. A Cronbach’s alpha of 0.7-
0.9 was considered acceptable [26,27].
Hypotheses were generated a priori to examine the extent to which baseline scores (construct 
validity) and 0-6 month change scores (longitudinal validity) on the RADAI-F5 were associated 
with baseline and 0-6 month change scores from other measures in a manner that was theoretically 
consistent [28]. Hypotheses for construct validity, which focused on baseline scores, were 
specified as follows: moderate positive correlations between the RADAI-F5 score and mRADAI-
5, FFI, and FIS domains; and a positive weak correlation between the RADAI-F5 score and the 
DAS-28 score. Hypotheses for longitudinal validity, which focused on 0-6 month change scores, 
were identical except for the FIS subscales, where a weak positive correlation was anticipated as 
the FIS is less responsive to change [29]. Spearman’s rank (rs) correlation and 95% confidence 
intervals (95%CI) were used to test these hypotheses and coefficients were interpreted as follows: 
0-0.1 = negligible, 0.1-0.39 = weak, 0.4-0.69 = moderate, 0.7-0.89 = strong, 0.9-1.0 = very strong 
[30]. 
The 1-week (test-retest) reliability was examined using a two-way mixed intra-class correlation 
coefficient (ICC) with corresponding 95% CIs for baseline and 1-week scores. Once preliminary 
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corresponding 95%CI for foot disease categories (remission, low, moderate, high) was calculated, 
with values of greater than 0.61 indicating substantial reliability [31].
Absolute measurement error was evaluated using the standard error of measurement (SEm), 
derived by dividing the SD of the mean change between the two measurements (SDchange/√2); the 
95% limits of agreement (LOA), derived by calculating the mean change between the two 
measurements, plus or minus 1.96 times the standard deviation of the changes ((meanchange) ± 1.96 
× (SDchange)); the 95% smallest detectable change (SDC95) (1.96 × √2 × SEm), and construction 
and examination of Bland-Altman plots [32-34].  
Responsiveness was evaluated using four different effect size statistics: Wilcoxon signed ranks 
test, Cohen’s d, the standardised response mean (SRM) and Guyatt’s Index [35]. In the absence of 
an anchor question to calculate minimal important difference (MID), MID was calculated using a 
value of 0.5 x SDchange scores between baseline and 6-months. Guyatt’s Index, representing the 
magnitude and variability in change scores relative to its MID was calculated as MID/√(2 x 
SDchange) [36]. Effect sizes were interpreted as follows:  <0.15 = negligible, >0.15-<0.40 = small, 
≥0.40-<0.75 = medium, ≥0.76-<1.10 = large, ≥1.10-<1.45 = very large, and >1.45 = huge [35].
Participants were classified according to mRADAI-5 thresholds for remission, mild, moderate or 
high disease activity. With participants assigned to the mRADAI-5 reference categories, the third 
quartile of corresponding RADAI-F5 scores were calculated to establish the thresholds for 
respective RADAI-F5 categories [24]. Cohen’s quadratic weighted kappa and 95% CI was used to 
evaluate agreement between disease activity categories between the mRADAI-5 and the RADAI-
F5.
Median (IQR) values were obtained for readability and relevant Likert scores, and completion 
time. For evaluation of floor and ceiling effects for the RADAI-F5 in the RA population, we 
adopted the conventional 15% threshold for patients achieving the highest and lowest scores to 
define and ceiling and floor effect respectively [32,37].
For the purposes of evaluating structural validity via factor analysis, a minimum sample size of 
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For hypotheses testing for construct and longitudinal validity, between 61 and 123 participants 
were required to detect at least weak correlation coefficients from 0.25-0.35 at 80% power and 
0.05 significance level (G*Power 3.1.9.2). 
RESULTS
A total of 142 participants (72.5% female) with a median (IQR) age of 55.5 (50-62) years and 
median (IQR) disease duration 10 (3.6-20.8) months took part, including 37 from the primary 
RADAI-F5 study and 105 from the RCT. A total of 84 participants completed the RADAI-F5 at 1-
week for reproducibility analyses, and 64 completed 6-month follow-ups for responsiveness 
analyses. Median (IQR) DAS28-ESR and mRADAI-5 scores indicate that participants were 
typically in a moderate disease activity state at study baseline (Table 1).  For DAS-28-ESR disease 
categories, 21.5% were in remission, 8.4% had low disease activity, 47.7 had moderate disease 
activity and 22.4% had high disease activity. Median (IQR) FFI, FIS impairment/footwear and 
activity limitation/participation restriction subscale scores suggest participants typically presented 
with moderate foot-related disability at baseline (Table 1).
Table 1. Sample baseline characteristics.
Dimensionality
The Kaiser-Meier-Olkin value of 0.83 and highly significant Bartlett test (p<0.001) indicate 
sampling adequacy and suitability for structure detection and factor analysis. Both Kaiser’s 
‘eignenvalue greater than one’ rule and scree plot examination suggested a one-factor solution, 
and this explained 73.18% of the common variance. Item loadings on the factor were uniformly 
greater than 0.4, indicating that all items contributed significantly to the aggregate score.
Internal consistency
High inter-item correlations (>0.8) were observed for questions 2 and 3, 2 and 4 and 3 and 4 of the 
questionnaire. Moderate inter-item correlations (>0.6) were observed for question 1 and 2, and 2 
and 5. All other inter-item correlations were between 0.4-0.6. Cronbach’s alpha was 0.90, 
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The RADAI-F5 had a weak positive correlation with the DAS-28 (rs 0.38, 95% CI 0.26-0.57, 
p<0.001) (Figure 1); a moderate positive correlation with the FIS impairment/footwear (rs 0.69, 
95% CI 0.66-0.82, p=<0.001) and FIS activity limitation/participation restriction subscales (rs 
0.48, 95% CI 0.37-0.63, p<0.001). Stronger positive correlations than predicted were observed for 
the mRADAI-5 (rs 0.79, 95% CI 0.73-0.85, p<0.001), and the FFI (rs 0.71, 95% CI 0.62-0.79, 
p<0.001) (Figure 1). Sixty per cent of associations for construct validity were in line with a priori 
hypotheses, and therefore largely theoretically consistent. Construct and longitudinal validity 
analyses are presented in Table 2.     
 Figure 1. 
Longitudinal validity
The RADAI-F5 had a weak positive correlation with the DAS28-ESR (rs 0.33, 95% CI 0.04-0.52, 
p=0.011); a moderate positive correlation with the mRADAI-5 (rs 0.66, 95% CI 0.41-0.74, 
p<0.01), the FFI (rs 0.60, 95% CI 0.47-0.77, p<0.001) and the FIS impairment/foowear subscale (rs 
0.43, 95% CI 0.09-0.56, p=0.001). A weaker positive correlation than predicted was observed for 
the FIS activity limitation/participation restriction subscale (rs 0.19, 95% CI -0.01-0.49, p=0.156), 
and the FFI (rs 0.71, 95% CI 0.62-0.79, p<0.01). Eighty per cent of associations for longitudinal 
validity were in line with a priori hypotheses.
Table 2. RADAI-F5 construct and longitudinal validity correlations for a priori hypotheses testing 
for associations with alternative disease activity and foot disability measures. 
Reliability
Mean (SD) RADAI-F5 scores for baseline and 1-week were 4.8 (2.58) and 4.91 (2.74). The mean 
(SD) difference between baseline and 1-week for the RADAI-F5 was 0.11 (1.37). The ICC (95%) 
for 1-week reproducibility was 0.87 (0.80-0.91, p=<0.001), indicating very good reproducibility.  
 
Absolute measurement error
The SEm value calculated for the RADAI-F5 from baseline and 1-week data was 0.97. This can be 
interpreted as follows; if a patient scores 3 on the RADAI-F5, we can be 68% confident that their 
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4.9. The LOA were -2.57 and 2.80.  From the Bland-Altman plot (Figure 2), we can identify that 
97.6% of differences between the two time-points were within the 95% limits. Exploration of the 
plot suggests there may be a minor funnel effect, with spread increasing slightly with increasing 
mean concentration (higher foot disease activity). The SDC95 value was estimated as 2.69, 
representing 26.9% of the RADAI-F5 scale maximum range, meaning that we can be 95% 
confident that a change score of 2.69 or more is a true change.  
Figure 2. 
Responsiveness
The RADAI-F5 exhibited high responsiveness to change over 6 months, as evidenced by a highly 
significant Wilcoxon signed-ranks tests (p<0.001) with very large effect size (0.91), Cohen’s d = 
0.64 (medium effect size), and an SRM = 0.97 (very large effect size). The MID value obtained 
from the distribution method (0.5 x SDchange) was 1.16, and the subsequent GI value calculated was 
0.70 (medium effect size). These values can be interpreted as a consistent pattern of medium to 
high responsiveness for the RADAI-F5.  
Interpretability 
For remission according to the mRADAI-5, the RADAI-F5 median and third quartile were 0.73 
and 1.0 (n=11). Therefore, the remission state was defined as a RADAI-F5 score ranging from 0-
1.0. The same procedure applied to define the disease categories for mild, moderate and high 
disease activity, resulted in the following ranges: >1-3.6 for mild disease activity (n=15), >3.6-5.7 
for moderate disease activity (n=42), and >5.7-10 for high disease activity (n=65) (table 3). 
Agreement between the RADAI-F5 and mRADAI-5 categories was good, as expressed by 72.5% 
exact agreement and Cohen’s quadratic weighted kappa (95% CI) of 0.71 (0.56-0.85). For the 
newly derived RADAI-F5 disease categories, agreement between baseline and 1-week was good, 
as expressed by 70.0% exact agreement and Cohen’s quadratic weighted kappa (95% CI) of 0.81 
(0.75-0.88).  Characteristics of disease and foot-related disability status within newly developed 
RADAI-F5 disease categories are shown in table 3.
Table 3. Participant characteristics according to RADAI-F5 foot disease activity categories 
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Content validity and practical burden
Participants largely considered the RADAI-F5 to be relevant for measuring foot disease activity in 
RA, with 53% and 29% indicating that it was relevant and extremely relevant respectively (Figure 
3A). Participants largely considered the RADAI-F5 to be easy to read and understand, with 45.8 
and 40% indicating that it was easy and very easy to read/understand respectively (Figure 3B). 
The median (IQR) time to complete the questionnaire was 5 (2-15) minutes. Overall it appears that 
the RADAI-F5 has good content validity, low completion burden. 
Figure 3. 
Floor/ceiling effects
 A total of 6 (4.33%) participants achieved the lowest possible RADAI-F5 score (0), and 0 (0%) 
participants achieved the highest possible score (10). Based on the 15% threshold levels, the 
RADAI-F5 does not exhibit a ceiling or floor effect.
DISCUSSION
We have developed and validated a 5-item PROM, named the Rheumatoid Arthritis Foot Disease 
Activity Index (RADAI-F5) to allow for the monitoring of inflammatory foot disease activity in 
people with established and early RA. The psychometric properties meet the recommended 
standards set by the International Society for Quality of Life Research (ISOQOL) [39] and the 
Consensus Based Standards for the Selection of Health Measurement Instruments (COSMIN) [40] 
demonstrating good construct validity, reliability, content validity, internal consistency, 
responsiveness and interpretability. The new PROM is designed to be quick and simple for 
patients to complete and clinicians to score and interpret, so that it can be used alongside 
composite disease activity indices in clinical practice. We anticipate that future use of the RADAI-
F5 as an adjunct to composite disease activity indices will improve local disease monitoring and 
may facilitate better medical management of foot disease activity. The RADAI-F5 may also be 
used alongside existing disease-specific foot disability PROMS such as the FIS in rehabilitation 
settings to distinguish between inflammatory and mechanical/functional foot impairments, which 
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possible that the RADAI-F5 could negate the need for composite disease activity scores to be 
recorded for RA foot research purposes (often collected to account for confounding).    
A key finding of this study is that evidence of convergent validity was observed between the 
RADAI-F5 and the mRADAI-5, and divergent validity between the RADAI-F5 and the DAS28-
ESR. This finding was anticipated a priori and is theoretically consistent with existing evidence 
demonstrating that composite disease activity indices that omit foot joints do not adequately 
capture foot synovitis [11]. Indeed, the majority of our a priori specified hypotheses were 
confirmed for strength of associations between disease activity/foot disability measures with the 
RADAI-F5. The correlation between RADAI-F5 and mRADAI-5 was slightly stronger than 
anticipated, but perhaps unsurprising given the similarities of these instruments. Another 
explanation is that relative to the DAS28-ESR, the mRADAI-5 has the ability to capture foot 
disease activity as it includes questions that cover all joints as a whole [16]. Importantly, RADAI-
F5 and mRADAI-5 scores were not perfectly correlated, and 72.5% agreement was observed 
between respective disease activity categories for each instrument, suggesting they capture local 
and global disease respectively.
The RADAI-F5 demonstrated very good reliability characteristics in terms of 1-week 
reproducibility of summary scores and agreement between baseline and 1-week disease categories. 
However, the SDC95 value (2.69) derived from the SEm (0.97) was larger than anticipated and 
exceeded the preliminary MID value (1.16) which was obtained via the distribution method. This 
means that if an individual patient has a change score as large as the preliminary MID, we cannot 
be 95% confident that this change is not due to measurement error [33]. This may be explained by 
the presence of outliers (Figure 3, and Figures 4-8 and Table 4 in supplementary material) rather 
than systematically large change scores. Inspection of outliers suggested a tendency for larger 
change scores in those with shorter disease durations. Moreover, the RADAI-F5 summary change 
scores appeared to be predominantly driven by larger change scores for individual items 4 (general 
foot health) and 5 (morning stiffness in the feet), which may be more unstable over shorter periods 
of time. This suggests that the instrument stability period of 1-week adopted here may be too long 
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changes in therapy such as administration of intra-muscular steroid could have affected 1-week 
scores. Anchor-based derivations of RADAI-F5 MID are now planned as these are recommended 
and should be assigned the most weight when estimating MID [38,42]. We recommend that 
population specific RADAI-F5 MID values are derived for future longitudinal studies seeking to 
measure changes in foot disease over time.
A strength of the RADAI-F5 is that it appears to demonstrate a consistent pattern of good 
responsiveness and theoretical consistency for longitudinal measurement, as has been reported for 
other global disease activity PROMs [16,43]. We evaluated responsiveness using data from a 
pragmatic trial comparing customised versus prefabricated foot orthoses plus routine medical care 
in early RA [25]. Whilst the responsiveness results over a 6-month period are promising, medical 
care was not standardised and so drugs and dosages varied between participants. Nevertheless, 
theoretically consistent associations for change scores between the RADAI-F5 and alternative 
instruments were observed, suggesting it could be used longitudinally to measure changes in foot 
disease activity in early RA. 
Preliminary foot disease category thresholds are proposed here to enhance applicability in routine 
clinical care in line with conventional categories adopted in other global disease activity PROMs 
and composite indices [24]. Whilst there is a relatively broad spectrum of RADAI-F5 scores in the 
study sample, we observed a negatively skewed distribution indicative of predominant moderate-
to-high foot disease activity within the sample. As a result, there were proportionally fewer 
participants allocated to ‘remission’ and ‘mild’ categories than the ‘moderate’ and ‘high’ 
categories. We also acknowledge that in the absence of a gold-standard outcome measure for 
quantifying foot disease activity, the mRADAI-5 (a global index of disease activity) was the best 
available reference score for establishing foot disease activity categories. Whilst threshold cut-offs 
appear to have good face validity, further evaluation utilising alternative approaches such as 
receiver operating characteristic curves may be appropriate.  Our future work will seek to confirm 
preliminary foot disease activity category thresholds reported here with greater focus on those 
with more established disease who are in remission or low global disease activity states.  We will 
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of persistent moderate foot disease in patients who are in low disease activity or remission states 
according to DAS28-ESR.     
We have confirmed the RADAI-F5 is valid, reliable, responsive, acceptable to patients, and 
potentially feasible for use in clinical practice in terms of ease of completion, quick scoring, and 
interpretability. The RADAI-F5 is freely available for use from 
www.gcu.ac.uk/centreforliving/radai-f5 and is recommended for use by rheumatologists and/or 
rheumatology nurse specialists alongside composite global disease activity indices; and Allied 
Health Professionals such as podiatrists and physiotherapists involved in delivering non-medical 
foot care in RA.     
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Sex, % female 72.5
Age in years, median (IQR) 55.5 (50-62) years
Disease duration in months, median (IQR) 10 (3.6-20.8) months
RADAI-F5 (0-10), median (IQR) 5.2 (3.2-7.3)
mRADAI-5 (0-10), median (IQR) 5.4 (3.4-7.2)
DAS28-ESR (0-10), median (IQR) 4.1 (2.84-4.92)
FFI (0-100), median (IQR) 45.9 (23.2-58.03)
FIS_IF (0-21), median (IQR) 13 (8.0-15.25)
















A priori hypothesis 
for association
Construct validity† 
mRADAI-5 (n=133) 0.79 (0.73-0.85)** Strong Moderate
DAS28-ESR (n=106) 0.38 (0.26-0.57)** Weak Weak
FFI (n=132) 0.71 (0.62-0.79)** Strong Moderate
FIS_IF (n=125) 0.69 (0.66-0.82)** Moderate Moderate
FIS_AP (n=124) 0.48 (0.37-0.63)** Moderate Moderate
Longitudinal validity‡  
mRADAI-5 (n=63) 0.66 (0.41-0.74)** Moderate Moderate
DAS28-ESR (n=60) 0.33 (0.04-0.52)* Weak Weak









This article is protected by copyright. All rights reserved
FIS_IF (n=63) 0.43 (0.01-0.56)** Moderate Weak
FIS_AP (n=63) 0.19 (-0.01-0.49) Weak Weak
** p<0.01, * p<0.05, †using baseline scores,  ‡using 0-6 month change scores
Table 3.










Female, % 75 62.1 89.2 33.3




144 (48-246) 10 (3-19) 7 (4-14) 11 (3-22)
DAS remission, 
n (%)
3 (2.9) 10 (9.5) 6 (5.7) 3 (2.9)
DAS low 
disease, n (%)
0 (0) 2 (1.9) 1 (1.0) 6 (5.7)
DAS moderate 
disease, n (%)
0 (0) 10 (9.5) 14 (13.3) 26 (24.8)
DAS high 
disease, n (%)
0 (0) 1 (1.0) 8 (7.6) 15 (14.3)
DAS28-ESR 1.76 (0.8-1.8) 2.91 (2.3-4.4) 4.13 (3.0-5.1) 4.33 (3.6-5.3)
mRADAI-5 0.6 (0.2-2.9) 3.2 (2.3-5.2) 5.2 (3.8-6.4) 7.2 (6.0-7.9)
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FIS_IF 0 (0-3.25) 8 (6-11.75) 12 (11-15) 15 (13-17)
FIS_AP 1.5 (0-8.25) 10 (4-15) 14 (10-22) 19 (16-24)
FIGURE LEGENDS
Figure 1. Scatterplots demonstrating convergent and divergent validity for RADAI-F5 
associations with (A) mRADAI-5 (n=133) and (B) DAS-28 ESR scores (n=106).
Figure 2. Bland-Altman plot for the RADAI-F5 summary score, with data points illustrating 
average scores from 2 time points separated by 1 week (n=84) against the difference between the 
corresponding baseline and 1 week scores, bias (solid line representing the average SD for 
baseline to 1 week scores for all participants), bias upper and lower 95% CI limits (light grey wide 
dashed line), and upper and lower LOA (dark grey narrow dashed line). 
Figure 3. Bar charts of participant responses (n=130) to RADAI-F5 relevance (A) and 
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